Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Vaccinex Inc (PK) VCNX

Healthcare Biotechnology
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment... see more

Current News (PINL:VCNX)

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease

GlobeNewswire December 23, 2025

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

GlobeNewswire May 27, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

GlobeNewswire April 21, 2025

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

GlobeNewswire March 7, 2025

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

GlobeNewswire December 17, 2024

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 18, 2024

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

GlobeNewswire November 7, 2024

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

GlobeNewswire November 5, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

GlobeNewswire October 31, 2024
View More News ››

Opinion & Analysis (PINL:VCNX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:VCNX)

Be the first to post on this bullboard.

McFarlane Lake Mining Ltd.

McFarlane Lake Mining Ltd.

McFarlane Lake Mining Limited engages in the acquisition and exploration of mineral resource properties in Canada. It ...
View More »

Podcasts